CEO Comments

As expected, the second quarter was not as strong in terms of sales as the first. However, we are making clear progress in our work to streamline the production process, which will generate positive effects over time. We also received our first order from the US for testing NLAB Saga® on a production scale. The company’s top priority continues to be the production of NLAB Saga®. During the quarter, we have introduced techniques to increase

SALES RECORD FOR A SINGLE QUARTER The first quarter of the year meant a sales record for a single quarter for the company and a good start to the new year. The ongoing positive customer dialogues combined with a continued stabilization of the production process create good conditions for increased sales growth during the year. Net sales for the quarter amounted to SEK 10,751 thousand and consist mainly of sales of our silica media NLAB

After many years of working with various technologies and products, Nanologica has developed into a pure chromatography company with products for purification of pharmaceuticals during production, on a global market. Today we provide pharmaceutical manufacturers with products that needed to manufacture  fast-growing GLP-1 analogues and insulin. With these products and our expertise in method and application development, we can streamline our customers’ workflows and reduce their costs. This makes us relevant in a market characterized

SALES RECORD FOR CHROMTOGRAPHY PRODUCTS In 2024, we reached our highest sales of chromatography products ever with net sales of SEK 14.5 million, of which SEK 6.7 million in the fourth quarter. Sales of our silica media NLAB Saga® were able to start during the summer after we finalized and approved significantly larger volumes of silica than before from our large-scale production facility. Production of silica has continued to stabilize during the year, which has

CEO COMMENT During the third quarter, we received our first recurring order for NLAB Saga® at a value of SEK 3.7 million from a customer in China. After the end of the quarter, we also received a supplementary order worth SEK 1.9 million from this customer, who is a producer of the fast-growing drug class GLP-1 analogues among other things. This is solid proof that NLAB Saga® works just as well as we expected also

We have now produced a number of consecutive large-scale batches within specifications which has enabled us to build up a stock of products for sale. We have also received our first slightly larger order for NLAB Saga® and we are now intensifying our sales efforts. It is very gratifying that the systematic work to further develop the large-scale production of our silica media NLAB Saga® has borne fruit – the plant now delivers significantly larger